Inclusion Criteria:

          -  Patients with suspected renal cell carcinoma with planned surgery or patients with
             metastatic RCC and a tissue diagnosis. (In standard clinical practice, biopsy is not
             routinely performed in patients who will be having surgery).

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Patient must be able to lie still for a 30 to 60 minute PET/CT scan.

          -  One of the following:

               1. Patients with locally advanced RCC planned for surgery determined to be a high
                  risk of recurrence, defined by presence of at least clinical T2 or thioredoxin 1
                  (TxN1), OR patients with metastatic RCC for whom treatment with metastasectomy is
                  planned by the treating physician.

               2. Patients with metastatic RCC for whom immuno-oncology (IO) therapy is planned.

          -  Women of child-bearing potential must agree to undergo and have documented a negative
             pregnancy test on the day of 89Zr-DFO-Atezolizumab administration. A female of
             child-bearing potential is any woman (regardless of sexual orientation, having
             undergone a tubal ligation, or remaining celibate by choice) who meets the following
             criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months).

        Exclusion Criteria:

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             atezolizumab or any other chimeric or humanized antibodies.

          -  Concurrent use of an immune checkpoint inhibitor (ICI).

          -  Uncontrolled severe and irreversible intercurrent illness or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Subjects must not be pregnant or nursing due to the potential for congenital
             abnormalities and the potential of this regimen to harm nursing infants.

          -  Significant autoimmune disease requiring treatment with either prednisone (or steroid
             equivalent) at a dose > 10 mg/day or other immunosuppressive agents. (Replacement
             steroid therapy is acceptable).

          -  Any patient for whom ICI therapy would be contraindicated for other reasons. Patients
             with adverse reactions to ICI therapy may undergo second 89Zr-DFO-Atezolizumab
             injection and PET/CT at the discretion of the treating physician considering that the
             dose of antibody represents 1% of a single therapeutic dose and therefore unlikely to
             cause adverse events.

          -  Subjects unable to provide informed consent.

          -  Subjects who are claustrophobic or have other contraindications to PET/CT.

          -  Subjects must not weigh more than the maximum weight limit for the table for the
             PET/CT scanner where the study is being performed. (>200 kg or 440 lbs).